StockData
Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc. (TVTX) stock

TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)

Close on Nov 17, 2026Market cap $4.82BP/E –Yield –

Travere Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Travere Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $227.14M, up 8.2% year over year. For fiscal 2026 it was $206.01M, down 5.3% from the year before. Over ten years it grew 15.1% a year on average. The highest annual figure on record is $244.99M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Dec 31, 2025$206.01M-5.3%
FY2025Dec 31, 2024$217.50M-11.2%
FY2024Dec 31, 2023$244.99M+7.8%
FY2023Dec 31, 2022$227.33M+13.0%
FY2022Dec 31, 2021$201.16M+52.7%
FY2021Dec 31, 2020$131.77M-6.5%
FY2020Dec 31, 2019$140.96M+13.9%
FY2019Dec 31, 2018$123.76M+58.3%
FY2018Dec 31, 2017$78.17M+10.4%
FY2017Dec 31, 2016$70.82M+40.4%
FY2016Dec 31, 2015$50.43M+5.5%
FY2015Dec 31, 2014$47.80M+574.7%
FY2014Dec 31, 2013$7.08M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2027Jun 30, 2026$60.28M+22.1%
Q1 FY2027Mar 31, 2026$57.09M+21.8%
Q4 FY2026Dec 31, 2025$57.87M-6.8%
Q3 FY2026Sep 30, 2025$51.89M+0.4%
Q2 FY2026Jun 30, 2025$49.36M-9.1%
Q1 FY2026Mar 31, 2025$46.89M-5.1%
Q4 FY2025Dec 31, 2024$62.07M+3.9%
Q3 FY2025Sep 30, 2024$51.68M-14.7%
Q2 FY2025Jun 30, 2024$54.33M-18.3%
Q1 FY2025Mar 31, 2024$49.42M-15.0%
Q4 FY2024Dec 31, 2023$59.75M+2.9%
Q3 FY2024Sep 30, 2023$60.59M+6.0%
Q2 FY2024Jun 30, 2023$66.49M+11.4%
Q1 FY2024Mar 31, 2023$58.16M+2.7%
Q4 FY2023Dec 31, 2022$58.09M+9.6%
Q3 FY2023Sep 30, 2022$57.15M+18.1%
Q2 FY2023Jun 30, 2022$59.68M+15.2%
Q1 FY2023Mar 31, 2022$56.61M+18.1%
Q4 FY2022Dec 31, 2021$53.00M+38.1%
Q3 FY2022Sep 30, 2021$48.41M+49.6%
Q2 FY2022Jun 30, 2021$51.81M+68.3%
Q1 FY2022Mar 31, 2021$47.95M+58.5%
Q4 FY2021Dec 31, 2020$38.39M+5.6%
Q3 FY2021Sep 30, 2020$32.35M-2.6%
Q2 FY2021Jun 30, 2020$30.79M-18.8%
Q1 FY2021Mar 31, 2020$30.25M-9.6%
Q4 FY2020Dec 31, 2019$36.37M+12.9%
Q3 FY2020Sep 30, 2019$33.22M+2.4%
Q2 FY2020Jun 30, 2019$37.93M+10.1%
Q1 FY2020Mar 31, 2019$33.44M+35.7%
Q4 FY2019Dec 31, 2018$32.21M+64.6%
Q3 FY2019Sep 30, 2018$32.45M+65.5%
Q2 FY2019Jun 30, 2018$34.46M+76.9%
Q1 FY2019Mar 31, 2018$24.64M+18.1%
Q4 FY2018Dec 31, 2017$19.58M-2.4%
Q3 FY2018Sep 30, 2017$19.61M+6.5%
Q2 FY2018Jun 30, 2017$19.48M–
Q1 FY2018Mar 31, 2017$20.86M–
Q4 FY2017Dec 31, 2016$20.06M–
Q3 FY2017Sep 30, 2016$18.41M–

More Travere Therapeutics figures

See a number that looks wrong?